EOX is a chemotherapy regimen used in the treatment of advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers.
For an oncology pharmacist, here’s the breakdown:
EOX Regimen
- E: Epirubicin (anthracycline, intercalates DNA and inhibits topoisomerase II → DNA strand breaks).
- O: Oxaliplatin (platinum compound, causes DNA cross-linking → apoptosis).
- X: Capecitabine (oral prodrug of 5-fluorouracil, antimetabolite inhibiting thymidylate synthase → impaired DNA synthesis).
Typical Schedule (every 3 weeks, for 6–8 cycles):
- Epirubicin: 50 mg/m² IV day 1
- Oxaliplatin: 130 mg/m² IV day 1
- Capecitabine: 625–1000 mg/m² PO BID, days 1–21 (continuous)
Clinical Use
- First-line treatment for advanced or metastatic gastric/GEJ adenocarcinoma.
- Alternative to ECF/ECX (where oxaliplatin is substituted for cisplatin for a more favorable toxicity profile).
Toxicities / Monitoring (key for pharmacists):
- Epirubicin: cardiotoxicity, myelosuppression, mucositis, alopecia.
- Oxaliplatin: peripheral neuropathy (acute cold-induced and cumulative), myelosuppression, hypersensitivity reactions.
- Capecitabine: hand-foot syndrome, diarrhea, mucositis, myelosuppression, cardiotoxicity (rare).
Pharmacist considerations
- Monitor cardiac function (due to epirubicin).
- Counsel on neuropathy precautions (avoid cold with oxaliplatin).
- Educate on hand-foot syndrome prevention and diarrhea management with capecitabine.
- Adjust doses for renal impairment (capecitabine, oxaliplatin).
- Drug-drug interaction check (especially with warfarin and capecitabine → INR increase).
In summary: EOX = Epirubicin + Oxaliplatin + Capecitabine, a gastric/GEJ cancer regimen designed as a more tolerable alternative to cisplatin-based regimens.